

- # Bundled Payment and Using Episode Groupers to Measure Specialist Performance

---

Robert Mechanic, MBA  
Jennifer Perloff, Ph.D

June 17, 2022

# Session Outline

## Part 1: Next steps for Medicare bundled payment and implications for ACOs

- Context for future CMS bundled payment policy
- Overview of BPCI-Advanced model
- Mitigating negative impact of Model overlap
- Considerations for ACO participation in bundles

## Part 2: Using episode groupers to measure specialist physician performance

# Context for Medicare Bundled Payment

---

- Current bundled payment models are ending
  - BPCI-A and OCM end after 2023
  - CJR ends after 2024
- CMMI wants to bring more value-based specialist care into ACOs
- New models likely for 2024
- Model overlap is a concern for ACOs

# MedPAC Supports a National Medicare Episode Model

---


- Participation could be mandatory\* for certain providers and clinical episodes
- Recommend ACO-attributed beneficiaries be included
- ACOs could incorporate episodes into their own contracts with providers
- Recommend CMMI continue limited testing of multiple episodes
- Different APMs should be designed to work together

\* Bundles would likely be mandatory for hospitals but not physicians.




# Evolution of Medicare Bundled Payment

# Medicare Bundled Payment



90-day look-forward

# Prospective



# Retrospective


- Target budget for each episode
- All providers paid FFS
- Periodic CMS settlements
  - Distribute surplus
  - Reclaim deficit
- Health system decides
  - Whom to contract with
  - How to distribute bonuses




# Bundle Risk and Risk Mitigation



# Medicare Cost per Case for 90-day Total Joint Replacement Episode (DRG 470): Sample Hospital (N=126)



# Medicare Cost per Case for 90-day Total Joint Replacement Episode (DRG 470): Sample Hospital (N=126)



# Evolution of Medicare Bundled Payment Approach

<b>BPCI Original</b>		<b>BPCI Advanced</b>
48 DRG-based clinical episodes (30, 60, 90 day)	→	31 inpatient and 4 outpatient episodes (90-day)
Target prices based on trended historical spending	→	Target prices based on national regression model
No risk adjustment. Only DRG case-mix adjustment	→	Prices adjusted for historical spend, patient characteristics, peer group and DRG mix
No quality measures	→	Gain or losses adjusted for quality (up to 10% of NPRA)
Participants select 1 – 48 episodes	→	Participants select 1 – 8 clinical service line groups (each multiple episodes)

# BPCI Clinical Episode Exclusions

## CLINICAL EPISODE EXCLUSIONS

The following are examples of what will be excluded from each Clinical Episode.

- **Excluded readmissions**– All Medicare Part A and Part B services furnished to a BPCI Advanced beneficiary during certain specified ACH admissions and readmissions (i.e., ACH admissions assigned at discharge to an MS-DRG for an organ transplant, trauma, cancer-related care, or ventricular shunts)
- **Excluded procedures** – Contralateral procedures with the same MS-DRG (e.g., MJRLE Clinical Episode that has a joint replaced in the opposite leg within 90 Days)
- **Excluded Cardiac Rehab Codes** – Payments for items and services for cardiac rehabilitation and intensive cardiac rehabilitation described in 42 C.F.R. § 410.49
- **Excluded Part B drugs; excluded IBD Part B drugs; excluded Hemophilia drugs**
- New technology add-on payments made pursuant to 42 C.F.R. § 412.87 and 42 C.F.R. § 412.88
- Payments for items and services with transitional pass-through payment status made pursuant to 42 C.F.R. § 419.62 and 42 C.F.R. § 419.66


Please review to the **MY4 Exclusion List** workbook to be posted in the BPCI Advanced website (<https://innovation.cms.gov/innovation-models/bpci-advanced>) for the specific MS-DRG and HCPCS code exclusions.

*CMS reserves the right to modify this list at any time to add or remove MS-DRGs and HCPCS codes.*

# Precedence Rules

## Precedence Rules for Episode Initiators


Potential Clinical Episode is identified.



# Model Overlap Rules


- Beneficiaries excluded from BPCIA
  - DCE/ACO REACH
  - MSSP Enhanced
  - Vermont and Maryland Models
  - Kidney Care models with downside risk
- Remember ... MedPAC recommends no exclusions
- DCE, ACO Reach, MSSP Enhanced can still participate for beneficiaries outside the ACO
- MSSP Basic Track ACO beneficiaries are not excluded but the ACOs are protected because reconciliation timing
- That means that CMS may pay double when overlap occurs

# Hypothetical Overlap Impact: Original BPCI



Overlap Impacts Will Differ Under BPCI-A

# Calculating Hospital Benchmark Price for Clinical Episodes



<sup>1</sup> Target price is benchmark price with 3% discount applied.

<sup>2</sup> Peer-group trend is set prospectively but adjusted retrospectively



# Calculating PGP Benchmark Prices

PGP	Hospital	Hospital Benchmark Price	PGP Relative Case Mix*	Episodes	PBP-ACH Benchmark Price
PGP 1	Hospital 1	\$32,000	0.92	55	\$29,440
PGP 1	Hospital 2	\$28,000	0.99	35	\$27,720
PGP 1	Hospital 3	\$26,000	1.02	102	\$26,520
PGP 1	Hospital 4	\$42,000	0.84	14	\$35,280
PGP 1	All				\$28,099

\*Ratio of PGP Patient Case Mix Adjustment (PCMA) Divided by Hospital PCMA

- BPCI-A Previously Had a Historical Adjustment for PGPs
- Adjustment reduced target prices for PGPs that were more efficient than the hospitals where they practice.
- A similar ACO “historical adjustment” is key for a “Fair” Overlap Policy

# Policy Options for Integrating Episodes

	ACO Beneficiaries	Non-ACO Beneficiaries	
ACO Providers	Option: ACO Precedence for Episodes	Option: Include Under ACO Financial Model	
External Providers	Ensure Fair Overlap Policy or Require ACO Contract	NA	

# Considerations for Participating in Episodes

---

- Are your ACO's hospitals and specialist physicians prepared for bundles?
- Is your ACO open to taking additional bundle risk for beneficiaries that are not in the ACO?
- Can you negotiate reasonable gainsharing arrangements with your hospitals and specialists?
- Can you use your participation to recruit new (engaged) specialists into your ACO?



- Engaging Medical Specialists with Episodes of Care

---



# Why Episodes?



- Provides information about cost and quality variation in specialty care
  - Engaging internal specialists
  - Profiling external specialists
- Insight into services and cost for acutely ill patients
  - Examine rates of acute events/procedures
  - Optimize care trajectories over time

# Options



- Home grown definitions
- CMMI Bundle Payment for Care Improvement (BPCI) bundles
- Consulting firm groupers (e.g., Millman)
- Commercial tools (e.g., ETGs, Cave)
- Patient Centered Episode System (PACES, open source)

# Not All Episode Groupers are Created Equal

---


- Individual bundles versus a full system
  - The bloated episode problem
- Triggering episodes on diagnosis or procedure, not an inpatient stay
  - Reward those who avert inpatient stays
  - Capture a broad view of the cohort of interest
- Different methods for allocating services to episodes (one of the trickiest parts of grouping!)
- Transparency

# PACES Core Concepts

- **Comprehensive** clinical taxonomy – every code has a home
- **Transparency** – definitions and rules are totally open for review
- **Patient-Centered** episodes – provider and setting agnostic
- Episodes are constructed using a consistent set of **robust and parsimonious rules**
- Recognizes **relationships among episodes**
  - Procedure episodes are “nested” within their indications
  - Episodes include their sequelae
- Expected costs are adjusted using patient level information
- **No double counting** of costs or savings



# The Whole vs the Sum of its Parts



# Nesting Episodes

Condition Episode



Colon Cancer Chronic Condition Episode of Care

June 1  
Diagnosis,  
Colonoscopy  
Dr. Smith, GI

June 3  
Pathology  
Dr. Jones, Pathologist

★ Dx ★

July - December  
Colectomy  
Dr. Pink,  
Oncologist

January -  
December  
Colectomy  
Dr. Pink,  
Oncologist

Nested Episodes



Surgery★

June 15  
Colectomy  
Dr. Green, General  
Surgeon

★ ★ Chemotherapy ★ ★

★ Monitoring ★

★ Indicates visits

# Number of Clinicians for Selected Procedural Episodes

Procedural Episode	Average Count of Unique Clinicians per Episode	Range
CABG	21	8-48
Colectomy	13	3-44
Mastectomy	9	4-16

# PACES Example: Background

---


- Large metropolitan hospital referral region (HRR)
- 2012-Q3 2015
- Colectomy procedure episodes
- Filters:
  - Zero dollar and low dollar cases
  - No inpatient stay assigned
  - (minimum service set)

# Key stratifications – surgical episodes of care

---

- Elective Case vs. Urgent/Emergent
- Indication
- Presence/absence of sequelae (proxy for quality)
- Clinical severity of the patient
- Resource use (low versus high)

# Profiling: Distribution of Observed Costs for Colectomy Episodes, Large Metropolitan HRR



**Key Points:**


- The interquartile range is almost \$18,000 and the upper one percent of cases cost over \$100,000
- This suggest room to improve efficiency

# Variation in Resource Use by Patient Severity

Spending Profile for Colectomy Episode in Sample HRR

	<b>Quartiles are Based on Patient HCC Scores</b>			
	<b>Low Risk</b>	<b>Medium Low Risk</b>	<b>Medium High Risk</b>	<b>High Risk</b>
Number	639	640	640	639
Mean	\$20,834	\$27,081	\$34,666	\$49,086
StdDev	\$7,940	\$11,995	\$16,140	\$31,325
P25	\$15,372	\$19,824	\$22,887	\$28,882
P50	\$19,957	\$23,731	\$30,954	\$41,110
P75	\$21,993	\$31,284	\$42,323	\$55,079

# Variation in Mean Colectomy Resource Use by TIN





# Observed-to-Expected and Sequelae Rate by TIN

TIN	N	Mean Total Episode Reimbursement, Observed	Mean Total Episode Reimbursement, Expected	Observed/Expected Ratio	Percent Reimbursement, Sequelae
434XXX	648	\$29,050	\$25,328	1.15	4.0%
428XXX	547	\$30,085	\$25,101	1.20	4.3%
391XXX	531	\$24,441	\$24,436	1.00	4.8%
370XXX	426	\$23,346	\$26,464	0.88	3.0%
421XXX	389	\$21,773	\$23,146	0.94	3.5%
222XXX	367	\$29,408	\$23,725	1.24	5.0%
427XXX	311	\$29,624	\$24,295	1.22	4.5%
621XXX	292	\$23,585	\$27,215	0.87	3.4%

- Four TINs with observed costs that are lower than expected cost
- 370701328 stands out for a low O/E ratio and low sequelae reimbursement

Episode ID	Sequelae Episode Name	How many times this COND is a sql of a TX episode?
345	<b>Electrolyte ds</b>	42
74	<b>Reparatory failure</b>	41
643	<b>Sepsis, SIRS</b>	41
206	<b>Fluid ds hypo/hyper-volemia</b>	39
141	<b>Post-op hemorrhage/hematoma</b>	38
1570	<b>Acute kidney failure</b>	36
641	<b>Post-op infection</b>	35
29	<b>Pneumonia</b>	31
982	<b>Anemia acute</b>	28
32	<b>Pneumonia aspiration</b>	27
165	<b>Acute myocardial infarction</b>	26
248	<b>Cellulitis, trunk and extremities</b>	26
660	<b>Surgical complctn nos</b>	25
1548	<b>UTI</b>	23
880	<b>Intestinal obstruction</b>	18
2177	<b>Heart failure (acute)</b>	16

## Sequelae at an Institutional or Provider Level

# Colectomy by Indication

	<b>All</b>	<b>Colorectal neoplasm malignant</b>				<b>Diverticulitis of colon</b>			
	<b>N</b>	<b>N</b>	<b>Observed</b>	<b>Expected</b>	<b>O/E</b>	<b>N</b>	<b>Observed</b>	<b>Expected</b>	<b>O/E</b>
428XXX	547	219	\$27,794	\$23,803	1.17	76	\$25,688	\$22,420	1.15
391XXX	531	180	\$22,031	\$22,658	0.97	78	\$26,299	\$25,768	1.02
370XXX	426	202	\$21,807	\$23,871	0.91	70	\$23,592	\$25,766	0.92
421XXX	389	140	\$21,807	\$22,811	0.96	72	\$18,394	\$23,687	0.78
222XXX	367	125	\$23,687	\$21,597	1.10	58	\$25,369	\$21,975	1.15
427XXX	311	119	\$27,466	\$22,342	1.23	62	\$28,729	\$23,628	1.22
621XXX	292	115	\$21,558	\$23,771	0.91	37	\$21,855	\$24,853	0.88

# TIN Comparison – Colectomy for Cancer

	TIN 043XXX	TIN 042XXX	TIN 391XXX	TIN 370XXX
<b>N</b>	312	245	187	209
<b>Pre-operative phase</b>				
<b>E&amp;M</b>	\$198	\$208	\$135	\$140
<b>Imaging/lab</b>	\$301	\$326	\$237	\$388
<b>Other</b>	\$231	\$292	\$66	\$161
<b>Intra-operative phase</b>				
<b>Index Inpatient Facility</b>	\$17,185	\$18,090	\$13,840	\$14,038
<b>Index Facility Outlier Payment</b>	\$1,081	\$1,135	\$188	\$883
<b>Index OP Facility Charges</b>	\$3	\$4	\$35	\$13
<b>Operating Clinician</b>	\$1,945	\$1,964	\$1,768	\$1,757
<b>Anesthesia</b>	\$473	\$456	\$365	\$436
<b>Imaging/lab</b>	\$229	\$294	\$248	\$180
<b>Other</b>	\$28	\$52	\$52	\$22
<b>Post-operative phase</b>				
<b>Inpatient Facility/Readmissions</b>	\$196	\$788	\$999	\$451
<b>PAC</b>	\$1,285	\$1,874	\$255	\$578
<b>Other</b>	\$1,807	\$1,422	\$1,026	\$723
<b>Sequelae</b>	\$4,793	\$4,450	\$3,106	\$2,612
<b>Total</b>	\$27,947	\$29,934	\$21,293	\$21,660

- Focal TIN also performed well on cancer surgery
- Strengths appear to be low readmissions and complications costs

# Challenges/Considerations

---

- **Severity mix within episodes**
  - Episode focused risk models, not generalized HCC models
- **Low volume specialist groups**
  - Pool multiple years of data to increase N
  - Look at multiple bundles for the same group

# Questions and Comments



Rob Mechanic, Executive Director  
[rmechanic@institute4ac.org](mailto:rmechanic@institute4ac.org)

Jen Perloff, Director of Research  
[jperloff@institute4ac.org](mailto:jperloff@institute4ac.org)